User:MastCell/To-do list

Top of the list

1. Helminthic therapy
2. Hairy cell leukemia
3. American Association of Physicians and Surgeons; incorporate New York Times ref
4. Passive smoking; incorporate Lancet article

Articles

• CPRIT
• PC-SPES
  • Herbal Remedies Turn Deadly for Patients, Washington Post
• Maharishi Vedic Approach to Health
  • Lancet 1990, PMID 1978105
  • New York Times 1992, "University's Degree Comes With a Heavy Dose of Meditation (and Skepticism)"
  • Providence Journal 1991, "Troubled times for the Maharishi Medical branch accused of deception, misinformation"
• Stomach cancer
  • Recent reviews:
    • Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010). Wagner, Anna Dorothea (ed.). "Chemotherapy for advanced gastric cancer". Cochrane Database Syst Rev (3): CD004064. doi:10.1002/14651858.CD004064.pub3. PMID 20238327.{{cite journal}}: CS1 maint: multiple names: authors list (link)
    • Pasini F, Fraccon AP, DE Manzoni G (2011). "The role of chemotherapy in metastatic gastric cancer". Anticancer Res. 31 (10): 3543–54. PMID 21965776.{{cite journal}}: CS1 maint: multiple names: authors list (link)
    • Yoong J, Michael M, Leong T (2011). "Targeted therapies for gastric cancer: current status". Drugs. 71 (11): 1367–84. doi:10.2165/11592530-000000000-00000. PMID 21812503.{{cite journal}}: CS1 maint: multiple names: authors list (link)

• Lyme disease
  • PMID 21810051
  • PMID 21867956
  • PMID 18452806

• Dietary supplements
  • De Smet PA (2004). "Health risks of herbal remedies: an update". Clin. Pharmacol. Ther. 76 (1): 1–17. doi:10.1016/j.clpt.2004.03.005. PMID 15229459.
  • Elvin-Lewis M (2005). "Safety issues associated with herbal ingredients". Adv. Food Nutr. Res. Advances in Food and Nutrition Research. 50: 219–313. doi:10.1016/S1043-4526(05)50007-X. ISBN 9780120164509. PMID 16263432.
  • List of adulterated dietary supplements from FDA

• TACT trial?
  • Why the NIH Trial to Assess Chelation Therapy (TACT) Should Be Abandoned
  • TACT stopped, theheart.org
  • Letter from OHRP
  • Review for NCCAM Is Overdue, Science 2006

• Werner Bezwoda?
  • JCO paper: Bezwoda WR, Seymour L, Dansey RD (1995). "High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial". J. Clin. Oncol. 13 (10): 2483–9. doi:10.1200/JCO.1995.13.10.2483. PMID 7595697.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • JCO retraction: "Retraction notice". J. Clin. Oncol. 19 (11): 2973. 2001. doi:10.1200/JCO.2001.19.11.2973. PMID 11387377.
  • Vickers A, Christos P (2000). "Bezwoda: evidence of fabrication in original article". J. Clin. Oncol. 18 (15): 2933. doi:10.1200/JCO.2000.18.15.2933. PMID 10920144.
  • Weiss RB, Gill GG, Hudis CA (June 2001). "An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications". J. Clin. Oncol. 19 (11): 2771–7. doi:10.1200/JCO.2001.19.11.2771. PMID 11387347.{{cite journal}}: CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  • Weiss RB, Rifkin RM, Stewart FM; et al. (March 2000). "High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study". Lancet. 355 (9208): 999–1003. doi:10.1016/S0140-6736(00)90024-2. PMID 10768448. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  • Horton R (2000). "After Bezwoda". Lancet. 355 (9208): 942–3. doi:10.1016/S0140-6736(00)90006-0. PMID 10768426.
  • Rettig, Richard (2007). False Hope: Bone Marrow Transplantation for Breast Cancer. Oxford University Press. ISBN 9780195187762. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  • Mukherjee, Siddhartha (2010). The Emperor of All Maladies. Scribner. ISBN 978-1439107959.
  • Grady, Denise (May 18, 1999). "Conference Divided Over High-Dose Breast Cancer Treatment". New York Times.
  • Grady, Denise (February 5, 2000). "Breast Cancer Researcher Admits Falsifying Data". New York Times.
  • Grady, Denise (March 10, 2000). "More Deception Is Suspected In Cancer Study". New York Times.
  • Cauvin, Henri (March 11, 2000). "Cancer Researcher in South Africa Who Falsified Data Is Fired". New York Times.
  • Maugh II, Thomas (April 27, 2001). "Key Breast Cancer Study Was a Fraud". Los Angeles Times. {{cite news}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  • Brownlee, Shannon (August 1, 2002). "Bad Science and Breast Cancer". Discover.

• RECORD trial
  • Wang AT, McCoy CP, Murad MH, Montori VM (2010). "Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review". BMJ. 340: c1344. doi:10.1136/bmj.c1344. PMC 2841746. PMID 20299696.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Nissen SE (March 2010). "Setting the RECORD Straight". JAMA. 303 (12): 1194–5. doi:10.1001/jama.2010.333. PMID 20332408.{{cite journal}}: CS1 maint: date and year (link)
  • Komajda M, McMurray JJ, Beck-Nielsen H; et al. (April 2010). "Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial". Eur. Heart J. 31 (7): 824–31. doi:10.1093/eurheartj/ehp604. PMC 2848325. PMID 20118174. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  • Home PD, Pocock SJ, Beck-Nielsen H; et al. (June 2009). "Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial". Lancet. 373 (9681): 2125–35. doi:10.1016/S0140-6736(09)60953-3. PMID 19501900. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  • Komajda M, Curtis P, Hanefeld M; et al. (2008). "Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)". Cardiovasc Diabetol. 7: 10. doi:10.1186/1475-2840-7-10. PMC 2390513. PMID 18435852. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  • Psaty BM, Furberg CD (July 2007). "The record on rosiglitazone and the risk of myocardial infarction". N. Engl. J. Med. 357 (1): 67–9. doi:10.1056/NEJMe078116. PMID 17551162.{{cite journal}}: CS1 maint: date and year (link)
  • Home PD, Pocock SJ, Beck-Nielsen H; et al. (July 2007). "Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis". N. Engl. J. Med. 357 (1): 28–38. doi:10.1056/NEJMoa073394. PMID 17551159. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  • Home PD, Pocock SJ, Beck-Nielsen H; et al. (September 2005). "Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol". Diabetologia. 48 (9): 1726–35. doi:10.1007/s00125-005-1869-1. PMID 16025252. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: date and year (link) CS1 maint: multiple names: authors list (link)
  • Harris, Gardiner (July 12, 2010). "Diabetes Drug Maker Hid Test Data, Files Indicate". New York Times. Retrieved July 12, 2010.
  • Harris, Gardiner (February 19, 2010). "Research Ties Diabetes Drug to Heart Woes". New York Times. Retrieved July 12, 2010.
  • Harris, Gardiner (September 12, 2007). "More Studies Cast Doubt on Safety of Diabetes Drug". New York Times. Retrieved July 12, 2010.
  • Harris, Gardiner (July 31, 2007). "Diabetes Drug Backed, but With Warnings". New York Times. Retrieved July 12, 2010.
  • Harris, Gardiner (February 22, 2010). "A Face-Off on the Safety of a Drug for Diabetes". New York Times. Retrieved July 12, 2010.
  • Harris, Gardiner (July 9, 2010). "Caustic Government Report Deals Blow to Diabetes Drug". New York Times. Retrieved July 12, 2010.
  • "FDA Briefing Document: Advisory Committee Meeting for NDA 21071 Avandia (rosiglitazone maleate) tablet" (PDF). U.S. Food and Drug Administration. July 13–14, 2010. Retrieved July 13, 2010. {{cite web}}: Check date values in: |date= (help)
  • Saul, Stephanie (January 31, 2008). "Doctor Accused of Leak to Drug Maker". New York Times. Retrieved July 13, 2010.
  • Vastag B (January 2008). "Reviewer leaked Avandia study to drug firm". Nature. 451 (7178): 509. doi:10.1038/451509a. PMID 18235464.{{cite journal}}: CS1 maint: date and year (link)
• serotonin syndrome
• Libby Zion
  • PMID 15784664
  • PMID 3347226
  • PMID 1952498
• AIDS-related lymphoma
• bone marrow transplant
• Dietary supplement
  • PMID 13129992
  • PMID 11601931
  • PMID 11268222
  • PMID 12490692
  • IOM report
  • CSPI report
  • Time magazine article
  • Another Time article
  • PMID 12490692 (NEJM)
• Graft-versus-host disease
• Hoxsey therapy
  • PMID 16565262
  • PMID 12233805
  • PMID 2104568
• Medical malpractice
• Medical resident work hours
• Chronic myeloid leukemia
• Multiple myeloma
• ‎The International Network of Cholesterol Skeptics
• TTP
• Alternative medicine:
  • [1]

Improvements

• Add section on published studies of ephedra
  • PMID 16552410
• Polycythemia - finish tidying up

To create?

Metabolife

• • Time magazine article
  • San Diego Union-Tribune article
  • Business Week article
  • USA Today article
  • CNN.com article
  • SD Union Tribune article on bankruptcy and fallout
  • USA Today article on charges that Metabolife lied to the FDA
  • SD Union-Trib article on income-tax evasion
  • DOJ press release on income-tax conviction
  • CBS News on allegations of lying to the FDA
  • Public Citizen letter to HHS Sec requesting investigation of Metabolife
  • Adverse Events report on Metabolife, prepared for the House Oversight Committee
  • SFgate: Metabolife and Gray Davis
  • Metabolife lawsuit
  • Slate.com on Metabolife vs the media
  • CBS News on guilty plea in income-tax case
  • Columbia Journalism Review on Metabolife's "pre-emptive strike" against bad press
  • Brief Time magazine article on supplement-industry lobbying
  • San Diego business journal on the aftermath of the bankruptcy
  • USNews and World Report on ephedra-industry allies within the FDA
  • The Austin Chronicle on ephedra lobbying efforts in Texas
  • SD Union-Trib on Dan Burton and Metabolife
  • SD Union-Trib on auction of Metabolife artwork to pay creditors

Andre Chad Parenzee

• • HIV experts line up to refute denier
  • Doubts on HIV's existence "insane"
  • HIV skeptics' claims out of date, judge told
  • HIV skeptics beyond stupid, says top scientist
  • HIV discoverer blasts doubters in SA court
  • Hogwash claim in HIV appeal
  • HIV deniers like UFO supporters, court told
  • HIV deniers "a joke"
  • Medic cans colleagues' HIV views
  • Expert attacks HIV sceptics
  • Verdict
  • Verdict
  • HIV claims thrown out by judge
  • Court Document: Verdict of the Supreme Court of South Australia (primary source)

Allegheny Health Education and Research Foundation (AHERF)

• • Speech by SEC staff
  • AHERF Case Study, from Casestudy.com (somewhat promotional, but contains useful info)
  • Drexel Accepts AHERF contract (aftermath)
  • The Fall of the House of AHERF, from medscape.com - quite detailed
  • Judge Wants AHERF payments returned (aftermath)
  • Judge approves AHERF settlement (aftermath)
  • $5.9M more sought for AHERF work
  • Lessons from the Allegheny Bankruptcy, from Penn's LDI
  • Court decision on AHERF retirement plan (primary source)
  • SEC press release: Complaint filed
  • Allegheny Doctor Sale, from Physicians Weekly
  • Income tax complaint against Sherif Abdel-Hak (primary source)
  • PA Dept of Health press release: Ride acts to monitor quality of care at AHERF
  • AHERF's Accountants charged by SEC, from Washington Post
  • Medical School's Last Chapter?, from Physicians Weekly
  • Anatomy of a Bankruptcy - excellent six-part series from the Pittsburgh Post-Gazette
  • Abdelhak plea ends AHERF saga
  • AHERF executive begins jail sentence
  • NY Times brief notice on Abdelhak's sentencing
  • Allegheny fees eat big part of payoffs, from the Philadelphia Inquirer.
  • SEC accuses 3 accountants in fraud suit, brief from the NY Times

International Society of the Built Environment

• • Indoor and Built Environment
  • Academics outed over smoke link, Sydney Morning Herald, 2/05
  • Their learned friends, article preview from The New Scientist, 1998
  • Tim Lambert's blog (probably doesn't meet WP:RS)
  • Tobacco cheifs In Spin Row, Daily Record, 2/05
  • Tobacco company set up network of sympathetic scientists, BMJ 1998;316:1553, PMID 11645059
  • PMID 15733724
  • Judge Gladys Kessler's Final Opinion Aria and IAI, pp. 1336-1340 (--Dessources 16:23, 22 August 2007 (UTC))
  • Please note that ISBE was not located in Geneva/Switzerland, contrary to what is said in the paper by Chapman. IAI (the name under which ISBE was founded in 1989) had its HQ in Rothenfluh, near Basel, in Switzerland. (--Dessources 16:23, 22 August 2007 (UTC))

Passive smoking

• • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • PMID 15911719: Review article on cardiovascular effects of passive smoking
  • PMID 15741361: Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry
  • Role of consulting scientists for the Tobacco Institute
  • List of consulting scientists